

Policy: MP302

Section: Medical Benefit Policy

Subject: Percutaneous Posterior Tibial Nerve Stimulation (PTNS)

Applicable Lines of Business

Commercial	X	CHIP	X
Medicare	X	ACA	X
Medicaid	X		

I. Policy: Percutaneous Posterior Tibial Nerve Stimulation (PTNS)

II. Purpose/Objective:

To provide a policy of coverage regarding Percutaneous Posterior Tibial Nerve Stimulation (PTNS)

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.

- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age.

DESCRIPTION:

Percutaneous Posterior Tibial Nerve Stimulation (PTNS) is a procedure that delivers retrograde access to the sacral nerve plexus via electrical stimulation of the posterior tibial nerve. Also referred to as posterior tibial nerve stimulation, this treatment is a minimally invasive form of neuromodulation used to treat overactive bladder (OAB) and the associated symptoms of urinary urgency, urinary frequency and urge incontinence.

INDICATIONS:

Percutaneous Posterior tibial nerve stimulation (PTNS) for the treatment of overactive bladder symptoms may be considered medically necessary, up to a maximum of 12 weeks when **ALL** of the following conditions are met:

- The member has had urinary dysfunction for at least 12 months and the condition has resulted in significant disability (i.e., the urinary urgency, frequency and or the severity of symptoms are limiting the member's ability to participate activities of daily living); **and**
- anatomical abnormalities of the lower urinary tract and active urinary tract infections have been excluded; **and**
- There is medical record evidence that the member has tried a minimum of 2 medications (e.g., alpha blockers and anticholinergics, and antibiotics for urinary tract infections) that have failed, are not well-tolerated, or are unable to be used due to contraindications.

LIMITATIONS:

The typical course of treatment will be considered to be 12 treatments of PTNS, 30 minutes, once-weekly.

Treatment beyond the initial 12 sessions will be allowed at a frequency of 1 every 1 to 2 months for up to two years if symptomatic improvement is documented.

Medicaid Business Segment:

This service will be considered for coverage only through a program exception.

EXCLUSIONS:

If the insured individual exhibits no improvement in OAB symptoms after 12 PTNS treatments, continued treatment is considered not medically necessary, and **NOT COVERED**

PTNS for the treatment of all other indications, is considered experimental, investigational or unproven and, is **NOT COVERED**.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

CODING ASSOCIATED WITH: Percutaneous Posterior tibial nerve stimulation

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.

CPT/HCPCS:

64566 Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes Programming

0587T Percutaneous implantation or replacement of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming and imaging guidance when performed, posterior tibial nerve

0588T Revision or removal of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve

0589T Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional,

posterior tibial nerve, 1-3 parameters
0590T Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters
Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS:

Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

Kurpad R, Kennelly MJ. The evaluation and management of refractory neurogenic overactive bladder. *Curr Urol Rep.* 2014;15(10):444

Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. *Neurourol Urodyn* 2012; 31(8):1206-16.

Yoong W, Shah P, Dadswell R, Green L. Sustained effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome: 2-year follow-up of positive responders. *Int Urogynecol J.* 2013 May;2(5):795-9.

Gaziev G, Topazio L, Iacovelli V, et al. Percutaneous tibial nerve stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. *BMC Urol.* 2013;13:61.

Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. *J Urol.* 2013 Jun; 189(6):2194-201.

Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Sham Efficacy in the Treatment of Overactive Bladder Syndrome: Results from the SUMiT Trial. *J Urol.* 2010;183:1438-43.

Gungor Ugurlucan F, Onal M, Asian E, Ayyildiz Erkan H, Kizilkaya Beji N, Yalcin O. Comparison of the effects of electrical stimulation and posterior tibial nerve stimulation in the treatment of overactive bladder syndrome. *Gynecol Obstet Invest.*2013;75(1):46-52.

Moosdorff-Steinhauser HF, Berghmans B. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review. *Neurourol Urodyn.* 2013;32(3):206-214.

Finazzi-Agro E, Petta F, Sciobica F et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. *J Urol* 2010; 184(5):2001-6.

Novitas Solutions. Local Coverage Determination (LCD): Surgery: Posterior Tibial Nerve Stimulation (PTNS) for Urinary Control (L35011)

Del Río-Gonzalez S, Aragon IM, Castillo E, et al. Percutaneous Tibial Nerve Stimulation Therapy for Overactive Bladder Syndrome: Clinical Effectiveness, Urodynamic, and Durability Evaluation. *Urology.* 2017 Oct;108:52-58

Yamashiro J, et al. New implantable tibial nerve stimulation devices: review of published clinical results in comparison to established neuromodulation devices. *Res Rep Urol* 2019 Dec 23;11:351-357

Hayes Health Technology Assessment. Percutaneous Tibial Nerve Stimulation For The Treatment Of Symptomatic Neurogenic Lower Urinary Tract Dysfunction. April 15, 2019, Feb. 2020

Welk B, McKibbin M. A randomized, controlled trial of transcutaneous tibial nerve stimulation to treat overactive bladder and neurogenic bladder patients. *Can Urol Assoc J.* Jul 2020; 14(7): E297-E303

This policy will be revised as necessary and reviewed no less than annually

Devised: 8/1/15

Revised: 8/16, 8/17 (revised title)

Reviewed: 8/18, 8/19, 8/20, 8/21, 8/22, 8/23

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.